Mechanistic Ancillary Studies to Ongoing Interventional Clinical Trials (R01) | Apply Online

Frequently Asked Questions (FAQs)

What is the purpose of the NIH/NIAMS funding opportunity "Mechanistic Ancillary Studies to Ongoing Interventional Clinical Trials (R01)" (RFA-AR-17-003)?

This opportunity is meant to fund add-on, mechanistic research projects that can be conducted alongside an interventional clinical trial that is already underway. The goal is to leverage the existing trial's enrolled (or enrolling) well-characterized participant cohort, operational infrastructure, clinical data collection, and often available biological specimens, to answer "how" and "why" questions about outcomes without starting a new trial from scratch.

What type of study does NIAMS want to support under this FOA?

NIAMS is looking for focused ancillary mechanistic studies that complement a parent interventional clinical trial. These ancillary projects typically add mechanistic endpoints and analyses such as assays, imaging, biomarker work, and other hypothesis-driven investigations intended to explain biological pathways, disease processes, or treatment response.

What qualifies as the required parent project for this ancillary study?

The parent project must be an ongoing interventional clinical trial. That means participants are prospectively assigned to receive an intervention (for example, a drug, biologic, device, procedure, or behavioral intervention), and outcomes are measured. The trial must be active enough that there is still time to incorporate the ancillary work.

Does the parent clinical trial need to be actively enrolling or already enrolled?

The FOA is designed to take advantage of a trial that already has enrolled (or is enrolling) a well-characterized patient cohort. The key practical point is that the trial must be underway and have sufficient remaining timeline to add the ancillary activities.

Can the ancillary study replace or duplicate the parent clinical trial?

No. The ancillary project is not intended to replace the parent trial or duplicate its goals. It must complement the parent study by adding mechanistic questions and measurements that help interpret the clinical outcomes.

What kinds of mechanistic activities are examples of a good fit?

Based on the FOA description, appropriate ancillary activities can include adding mechanistic endpoints, laboratory assays, imaging measures, biomarker discovery/validation approaches, or other hypothesis-driven investigations that clarify biological pathways and disease processes connected to the intervention and outcomes measured in the parent trial.

What does NIAMS mean by "mechanistic rationale and premise"?

Applicants are expected to present a clear biological or pathophysiological question, explain why that question is important, and show a convincing link between the parent trial intervention and the mechanism to be studied. The application should justify how the proposed measurements will illuminate disease processes or treatment response, rather than simply adding descriptive or unrelated data collection.

Why must the ancillary work be time-sensitive?

The FOA emphasizes that the ancillary work must be tied to the timeline of the ongoing trial. The opportunity to collect critical samples, capture a particular disease state, or measure specific responses may only exist while the parent trial is still conducting interventions and follow-up. If the ancillary study starts too late, key data or specimens could no longer be obtainable.

What does "accelerated review and award process" imply for applicants?

NIAMS indicates applications will undergo an accelerated review and award process to match the time-sensitive nature of the work. Applicants are expected to clearly explain why rapid funding is necessary and why the project cannot wait for a standard review cycle if it is to capitalize on the parent trial's current activities.

What operational planning details should be included in an application?

The FOA expects a timeline demonstrating that the parent trial has enough time remaining to incorporate the ancillary work. Applicants should describe how and when samples will be collected, when assays or other measurements will be performed, when and how ancillary data will be linked to clinical outcomes, and how ancillary tasks align with the remaining milestones of the parent study.

What parent-trial resources make this ancillary approach efficient?

The FOA highlights that the parent trial should provide an established cohort, a functioning operational/clinical infrastructure, access to clinical data, and access to biological materials (or the ability to collect them) within the remaining timeframe of the trial.

Is documentation of permission from the parent trial required?

Yes. A non-negotiable requirement is documentation showing the ancillary study has permission from the parent project to use its participants, data, and biological materials. Because these resources are controlled by the parent trial leadership, applicants must demonstrate that necessary agreements and access are in place.

What kinds of coordination issues does NIAMS expect applicants to address with the parent trial?

While the FOA does not prescribe specific documents, it indicates the need for coordination around participant consent, specimen use permissions, data sharing, governance, and logistics. Applicants also need to ensure ancillary activities do not compromise the integrity, safety, or primary objectives of the parent trial.

What scientific areas does the ancillary study need to align with?

The ancillary study must align with NIAMS mission areas. The FOA generally references diseases and conditions involving arthritis and musculoskeletal and skin biology, and applicants are expected to ensure their specific topic fits NIAMS priorities.

What is NIAMS trying to achieve by funding mechanistic ancillary studies instead of new trials?

Programmatically, NIAMS is using this mechanism to leverage existing investments in major clinical trials. By adding mechanistic depth to an ongoing trial, NIAMS aims to maximize scientific return without the cost and time required to launch a new interventional clinical trial.

What kinds of outcomes or insights are intended from successful ancillary studies?

The FOA describes intended payoffs such as increasing the scientific value of the parent trial, deepening understanding of NIAMS-relevant diseases or organ systems, and potentially revealing new targets for diagnosis, prevention, or treatment. Examples of mechanistic insights mentioned include identifying biomarkers that predict response, clarifying immune or inflammatory pathways affected by the intervention, uncovering tissue-level changes linked to clinical improvement, and explaining heterogeneity in outcomes across patient subgroups.

What grant mechanism is used for this opportunity?

This is an R01 grant mechanism.

What is the Health activity category and CFDA number listed for this FOA?

The activity category is Health, and the CFDA number listed is 93.846.

What is the listed award ceiling for this opportunity?

The award ceiling listed in the provided information is $300,000.

When was this FOA posted and what was the application closing date?

The FOA was posted February 5, 2016, and the application closing date was April 3, 2017. The dates indicate this specific announcement is historical.

Who is eligible to apply based on the information provided?

Eligibility is described as broad and includes many types of U.S. entities: federally recognized tribal governments and organizations, state and local governments, public and private institutions of higher education, nonprofit organizations (with or without 501(c)(3) status), for-profit organizations (including small businesses), and other applicants as allowed by the FOA's additional eligibility language.

What is the key message NIAMS is sending to prospective applicants?

NIAMS is looking for well-coordinated, scientifically compelling, rapidly deployable ancillary mechanistic studies that can be executed within the remaining window of an active interventional clinical trial and that meaningfully amplify what that trial can teach the field.